• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Drugmakers Lash Back at Insurers in War of Words Over Rx Prices

Article

After enduring a rhetorical bashing over the cost of hepatitis C wonder drug Sovaldi, drug manufacturers released a study this week documenting the high cost-sharing rates charged by some insurers on health plans sold through the public exchanges.

The pharmaceutical industry is fighting back.

After enduring a rhetorical bashing over the cost of hepatitis C wonder drug Sovaldi, drug manufacturers released a study this week documenting the high cost-sharing rates charged by some insurers on health plans sold through the public exchanges.

The study was conducted by the consulting firm Avalere Health on behalf of Pharmaceutical Research and Manufacturers of America, the main industry group. It looked at drug formularies on 123 silver plans, which are designed to cover 70% of medical costs, including at least one plan sold in the largest city in every state.

Read the full story here: http://bit.ly/1qkmDOp

Source: Modern Healthcare

Related Videos
Leslie Fish, PharmD.
Ronesh Sinha, MD
Adam Colborn, JD
Beau Raymond, MD
Judith Alberto, MHA, RPh, BCOP, director of clinical initiatives, Community Oncology Alliance
Yuqian Liu, PharmD
Jenny Craven, PharmaD, BCPS
Kimberly Westrich, MA
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Sarah Bajorek, PhD, BCACP, MBA.
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.